- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 317/22 - Radicals substituted by singly bound oxygen or sulfur atoms etherified
Patent holdings for IPC class C07D 317/22
Total number of patents in this class: 104
10-year publication summary
|
7
|
12
|
5
|
8
|
4
|
7
|
7
|
3
|
11
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21303 |
6 |
| ENI S.p.A. | 1307 |
6 |
| JSR Corporation | 2555 |
4 |
| Promega Corporation | 589 |
4 |
| Eisai R&D Management Co., Ltd. | 1166 |
4 |
| Gfbiochemicals Limited | 50 |
3 |
| Gilead Sciences, Inc. | 2220 |
3 |
| The Regents of the University of California | 20720 |
2 |
| Bayer Schering Pharma AG | 317 |
2 |
| FUJIFILM Corporation | 30512 |
2 |
| Ambrx, Inc. | 169 |
2 |
| NOK Corporation | 2296 |
2 |
| Symrise AG | 1844 |
2 |
| Toyo Gosei Co., Ltd. | 106 |
2 |
| University of Connecticut | 881 |
2 |
| Melchior Material and Life Science France | 36 |
2 |
| Berlirem GmbH | 5 |
2 |
| Beijing Tienyi Lufu PharmaTech Co. Ltd. | 6 |
2 |
| NanoVation Therapeutics Inc. | 87 |
2 |
| Specialty Operations France | 916 |
2 |
| Other owners | 48 |